Textiles Press Releases
SEE OTHER BRANDS

Your best source on the textile industry news from the world

Textiles Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Textiles Press Releases.

Press releases published on June 16, 2025

ParaZero Demonstrates 50 Successful DropAir Deployments as Part of a Decisive Reproducibility Test

ParaZero Demonstrates 50 Successful DropAir Deployments as Part of a Decisive Reproducibility Test

Kfar Saba, Israel, June 16, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace company focused on safety systems for commercial unmanned aerial systems and counter UAS systems, today announced the …

TEGNA Announces Major Local News Expansion: Adding More than 100 Hours of New Daily Programming Across 50+ Markets

TEGNA Announces Major Local News Expansion: Adding More than 100 Hours of New Daily Programming Across 50+ Markets

TYSONS, Va., June 16, 2025 (GLOBE NEWSWIRE) -- TEGNA Inc. (NYSE: TGNA) today announced that its stations will be significantly expanding their already substantial local news programming by launching live and on-demand, local newscasts from 7 to 9 a.m. …

NFI subsidiary New Flyer signs a major contract with New Jersey Transit for up to 750 buses

NFI subsidiary New Flyer signs a major contract with New Jersey Transit for up to 750 buses

ST. CLOUD, Minn., June 16, 2025 (GLOBE NEWSWIRE) -- (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI, or the Company) a leader in innovative, propulsion-agnostic bus and coach mobility solutions, subsidiary New Flyer of America Inc. (New Flyer), …

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

LOUISVILLE, Ky., June 16, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Nuvation Bio Inc. for IBTROZI™ (taletrectinib), a kinase inhibitor approved for the treatment of …

Plato Gold Announces Closing of Loan Financing  for First Ever Drill Program  at Lolita Project, Santa Cruz, Argentina

Plato Gold Announces Closing of Loan Financing for First Ever Drill Program at Lolita Project, Santa Cruz, Argentina

Toronto, June 16, 2025 (GLOBE NEWSWIRE) -- Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (FRANKFURT: 4Y7 OR WKN: A0M2QX) (“Plato” or the “Company”) an exploration company with a portfolio of properties in Northern Ontario and Santa Cruz, Argentina announces …

Discovery Announces Management Appointments

Discovery Announces Management Appointments

TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today announced the hiring of Amy Hu as Senior Vice President, Legal and Sustainability and Darin Smith as Senior Vice President, …

Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology

Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology

Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technology Research builds on Emory’s research on influenza vaccines self-administered via …

Caledonia Mining Corporation Plc: Utilisation of the block admission in respect of ATM Sales Agreement

Caledonia Mining Corporation Plc: Utilisation of the block admission in respect of ATM Sales Agreement

ST HELIER, Jersey, June 16, 2025 (GLOBE NEWSWIRE) -- In accordance with Rule 29 of the AIM Rules for Companies (“the AIM Rules”), Caledonia Mining Corporation Plc (“Caledonia” or “the Company”) (NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL) gives below the …

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rights Phase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025 Initial Phase 1 …

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared …

Mark Ford Joins Highway as Chief Capacity Officer

Mark Ford Joins Highway as Chief Capacity Officer

DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Highway announced today that Mark Ford will join the company as Chief Capacity Officer, a strategic addition to the executive team as the company accelerates growth and advances its long-term vision to redefine …

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions

– Hengrui to present six abstracts highlighting clinical progress of GLP-1/GIP dual receptor agonist HRS9531 (KAI-9531) and GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes and obesity – JIANGSU, China and BOSTON, June 16, 2025 (GLOBE NEWSWIRE …

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® ( …

Fury Finalizes Drill Targeting at its Newly Acquired Sakami Gold Project

Fury Finalizes Drill Targeting at its Newly Acquired Sakami Gold Project

TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to announce that is has finalized a number of drill targets at the Sakami gold project located in the Eeyou Istchee …

Nokia announces changes to Group Leadership Team

Nokia announces changes to Group Leadership Team

Nokia Corporation Stock Exchange Release 16 June 2025 at 14:00 EEST Nokia announces changes to Group Leadership Team Federico Guillén to retire from Nokia on 31 December 2025. He will step down as President of the Network Infrastructure (NI) business group …

Nokia ilmoittaa muutoksista johtoryhmän kokoonpanossa

Nokia ilmoittaa muutoksista johtoryhmän kokoonpanossa

Nokia Oyj Pörssitiedote 16.6.2025 klo 14:00 EEST Nokia ilmoittaa muutoksista johtoryhmän kokoonpanossa Federico Guillén jää eläkkeelle tehtävistään Nokiassa 31.12.2025. Hän jättää tehtävänsä Nokian Verkkoinfrastruktuuri-liiketoimintaryhmän johtajana ja …

Eolo Pharma Publishes First-in-Human Study in Nature Metabolism on Novel Obesity Drug Activating Energy-Burning Pathway

Eolo Pharma Publishes First-in-Human Study in Nature Metabolism on Novel Obesity Drug Activating Energy-Burning Pathway

- New data show clinical safety and early efficacy of SANA, a first-in-class compound that targets creatine-dependent thermogenesis MONTEVIDEO, Uruguay, June 16, 2025 (GLOBE NEWSWIRE) -- Eolo Pharma, a clinical-stage biotechnology company developing …

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that …

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile— —Patients report improved quality of life and daily functioning with ORLADEYO— RESEARCH TRIANGLE PARK, N.C., June 16, …

Giyani Receives Letter of Interest from EXIM for US$225 million

Giyani Receives Letter of Interest from EXIM for US$225 million

TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- Giyani Metals Corp. (TSXV:EMM, GR:A2DUU8) ("Giyani" or the "Company"), developer of the K.Hill Battery-Grade Manganese Project in Botswana ("K.Hill" or “the Project”), is pleased to announce that it received a non …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service